随着人民生活水平的快速提高和国民经济的飞速发展,人们的饮食和生活习惯发生巨大改变,肥胖发病率的逐年递增,减肥产品越来越受欢迎,并且在柜台上可以买到各种各样的这些产品。长期以来,用于减肥的产品包括化学药、保健品、膳食补充剂等。因此,为了让肥胖患者了解减肥产品并做出更好的选择,本文对一些减肥产品临床效果及作用机制进行综述。
With the rapid improvement of people’s living standards and the rapid development of national economy, people's diet and living habits have changed greatly, the incidence of obesity is increasing year by year, weight loss products are more and more popular, and you can buy a variety of these products on the counter. Products for weight loss have long included chemicals, health supplements and dietary supplements. Therefore, in order to help obese patients understand weight-loss products and make better choices, this paper reviews the clinical effects and mechanisms of some weight-loss products.
With the rapid improvement of people’s living standards and the rapid development of national economy, people's diet and living habits have changed greatly, the incidence of obesity is increasing year by year, weight loss products are more and more popular, and you can buy a variety of these products on the counter. Products for weight loss have long included chemicals, health supplements and dietary supplements. Therefore, in order to help obese patients understand weight-loss products and make better choices, this paper reviews the clinical effects and mechanisms of some weight-loss products.
梁 淑,黄 蓉,王略力,陈 晨,方 雁,杜晓华,肖创,杨为民. 减肥产品及其药理作用机制研究进展 Research Progress of Slimming Products and Their Pharmacological Mechanisms[J]. 食品与营养科学, 2022, 11(01): 73-79. https://doi.org/10.12677/HJFNS.2022.111009
参考文献ReferencesTak, Y.J. and Lee, S.Y. (2021) Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. The World Journal of Men’s Health, 39, 208-221. <br>https://doi.org/10.5534/wjmh.200010Ng, M., Fleming, T., Robinson, M., et al. (2014) Global, Regional, and National Prevalence of Overweight and Obesity in Children and Adults during 1980-2013: A Systematic Analysis for the Global Burden of Disease Study 2013. The Lancet, 384, 766-781. <br>https://doi.org/10.1016/S0140-6736(14)60460-8Afshin, A., Forouzanfar, M.H., Reitsma, M.B., et al. (2017) Health Effects of Overweight and Obesity in 195 Countries over 25 Years. The New England Journal of Medicine, 377, 13-27. <br>https://doi.org/10.1056/NEJMoa1614362Lauby-Secretan, B., Scoccianti, C., Loomis, D., et al. (2016) Body Fatness and Cancer—Viewpoint of the IARC Working Group. The New England Journal of Medicine, 375, 794-798. <br>https://doi.org/10.1056/NEJMsr1606602Efsa Panel on Dietetic Products N, Allergies (2011) Scien-tific Opinion on the Substantiation of Health Claims Related to Chitosan and Reduction in Body Weight (ID 679, 1499), Maintenance of Normal Blood LDL-Cholesterol Concentrations (ID 4663), Reduction of Intestinal Transit Time (ID 4664) and Reduction of Inflammation (ID 1985) Pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 9, 2214. <br>https://doi.org/10.2903/j.efsa.2011.2214Mesa Ospina, N., Ospina Alvarez, S.P., Escobar Sierra, D.M., et al. (2015) Isolation of Chitosan from Ganoderma lucidum Mushroom for Biomedical Applications. Journal of Materials Science: Materials in Medicine, 26, 135.
<br>https://doi.org/10.1007/s10856-015-5461-zWalsh, A.M., Sweeney, T., Bahar, B., et al. (2013) Mul-ti-Functional Roles of Chitosan as a Potential Protective Agent against Obesity. PLoS ONE, 8, e53828. <br>https://doi.org/10.1371/journal.pone.0053828Moraru, C., Mincea, M.M., Frandes, M., et al. (2018) A Me-ta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure. Medicina (Kaunas), 54, 109. <br>https://doi.org/10.3390/medicina54060109Ganesan, K. and Xu, B. (2017) Polyphenol-Rich Dry Common Beans (Phaseolus vulgaris L.) and Their Health Benefits. International Journal of Molecular Sciences, 18, 2331. <br>https://doi.org/10.3390/ijms18112331Udani, J., Tan, O. and Molina, J. (2018) Systematic Review and Me-ta-Analysis of a Proprietary Alpha-Amylase Inhibitor from White Bean (Phaseolus vulgaris L.) on Weight and Fat Loss in Humans. Foods, 7, 63.
<br>https://doi.org/10.3390/foods7040063Maccioni, P., Colombo, G., Riva, A., et al. (2010) Reducing Effect of a Phaseolus vulgaris Dry Extract on Operant Self-Administration of a Chocolate-Flavoured Beverage in Rats. British Journal of Nutrition, 104, 624-628.
<br>https://doi.org/10.1017/S0007114510001017Velickovic, K., Wayne, D., Leija, H.A.L., et al. (2019) Caffeine Exposure Induces Browning Features in Adipose Tissue in Vitro and in Vivo. Scientific Reports, 9, Article No. 9104. <br>https://doi.org/10.1038/s41598-019-45540-1Naveed, M., Hejazi, V., Abbas, M., et al. (2018) Chlorogenic Acid (CGA): A Pharmacological Review and Call for Further Research. Biomedicine & Pharmacotherapy, 97, 67-74. <br>https://doi.org/10.1016/j.biopha.2017.10.064Stefanello, N., Spanevello, R.M., Passamonti, S., et al. (2019) Coffee, Caffeine, Chlorogenic Acid, and the Purinergic System. Food and Chemical Toxicology, 123, 298-313. <br>https://doi.org/10.1016/j.fct.2018.10.005Wang, Z., Lam, K.L., Hu, J., et al. (2019) Chlorogenic Acid Allevi-ates Obesity and Modulates Gut Microbiota in High-Fat-Fed Mice. Food Science & Nutrition, 7, 579-588. <br>https://doi.org/10.1002/fsn3.868Thom, E. (2007) The Effect of Chlorogenic Acid Enriched Coffee on Glucose Absorption in Healthy Volunteers and Its Effect on Body Mass When Used Long-Term in Overweight and Obese People. Journal of International Medical Research, 35, 900-908. <br>https://doi.org/10.1177/147323000703500620Haidari, F., Samadi, M., Mohammadshahi, M., et al. (2017) Energy Restriction Combined with Green Coffee Bean Extract Affects Serum Adipocytokines and the Body Composition in Obese Women. Asia Pacific Journal of Clinical Nutrition, 26, 1048-1054.Flanagan, J., Bily, A., Rolland, Y., et al. (2014) Lipolytic Activity of Svetol®, a Decaffeinated Green Coffee Bean Extract. Phytotherapy Research, 28, 946-948. <br>https://doi.org/10.1002/ptr.5085Liu, G., Huang, Y., Reis, F.S., et al. (2019) Impact of Nutritional and Environmental Factors on Inflammation, Oxidative Stress, and the Microbiome 2019. BioMed Research International, 2019, Article ID: 5716241.
<br>https://doi.org/10.1155/2019/5716241Yang, C.S. and Hong, J. (2013) Prevention of Chronic Diseases by Tea: Possible Mechanisms and Human Relevance. Annual Review of Nutrition, 33, 161-181. <br>https://doi.org/10.1146/annurev-nutr-071811-150717Glisan, S.L., Grove, K.A., Yennawar, N.H., et al. (2017) Inhibition of Pancreatic Lipase by Black Tea Theaflavins: Comparative Enzymology and in Silico Modeling Studies. Food Chemistry, 216, 296-300.
<br>https://doi.org/10.1016/j.foodchem.2016.08.052Wolfram, S., Raederstorff, D., Wang, Y., et al. (2005) TEAVIGO (Epigallocatechin Gallate) Supplementation Prevents Obesity in Rodents by Reducing Adipose Tissue Mass. Annals of Nutrition and Metabolism, 49, 54-63.
<br>https://doi.org/10.1159/000084178Wu, C.H., Lu, F.H., Chang, C.S., et al. (2003) Relationship among Habit-ual Tea Consumption, Percent Body Fat, and Body Fat Distribution. Obesity Research, 11, 1088-1095. <br>https://doi.org/10.1038/oby.2003.149Chen, I.J., Liu, C.Y., Chiu, J.P., et al. (2016) Therapeutic Effect of High-Dose Green Tea Extract on Weight Reduction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clinical Nutrition, 35, 592-599.
<br>https://doi.org/10.1016/j.clnu.2015.05.003Orlistat, M. (2012) LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda.Beyea, M.M., Garg, A.X. and Weir, M.A. (2012) Does Orlistat Cause Acute Kidney Injury? Therapeutic Advances in Drug Safety, 3, 53-57. <br>https://doi.org/10.1177/2042098611429985Panda, S.R., Jain, M., Jain, S., et al. (2018) Ef-fect of Orlistat versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Ran-domized Control Trials. The Journal of Obstetrics and Gynecology of India, 68, 336-343. <br>https://doi.org/10.1007/s13224-018-1140-6Apovian, C.M., Aronne, L., Rubino, D., et al. (2013) A Random-ized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-Related Risk Factors (COR-II). Obesity (Silver Spring), 21, 935-943.
<br>https://doi.org/10.1002/oby.20309Fujioka, K. and Braverman-Panza, J. (2016) Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. The Journal of Family Practice, 65, S16-S23.Hollander, P., Gupta, A.K., Plodkowski, R., et al. (2013) Effects of Naltrexone Sus-tained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Over-weight and Obese Patients with Type 2 Diabetes. Diabetes Care, 36, 4022-4029. <br>https://doi.org/10.2337/dc13-0234Melnikova, I. and Wages, D. (2006) Anti-Obesity Therapies. Nature Re-views Drug Discovery, 5, 369-370.
<br>https://doi.org/10.1038/nrd2037Toplak, H., Hamann, A., Moore, R., et al. (2007) Efficacy and Safety of To-piramate in Combination with Metformin in the Treatment of Obese Subjects with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study. International Journal of Obesity (London), 31, 138-146. <br>https://doi.org/10.1038/sj.ijo.0803382Allison, D.B., Gadde, K.M., Garvey, W.T., et al. (2012) Con-trolled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). Obesity (Silver Spring), 20, 330-342.
<br>https://doi.org/10.1038/oby.2011.330Gadde, K.M., Allison, D.B., Ryan, D.H., et al. (2011) Effects of Low-Dose, Controlled-Release, Phentermine plus Topiramate Combination on Weight and Associated Comorbidities in Overweight and Obese Adults (CONQUER): A Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 377, 1341-1352.
<br>https://doi.org/10.1016/S0140-6736(11)60205-5Garvey, W.T., Ryan, D.H., Look, M., et al. (2012) Two-Year Sustained Weight Loss and Metabolic Benefits with Controlled-Release Phentermine/Topiramate in Obese and Overweight Adults (SEQUEL): A Randomized, Placebo-Controlled, Phase 3 Extension Study. The American Journal of Clinical Nutrition, 95, 297-308.
<br>https://doi.org/10.3945/ajcn.111.024927Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. (2016) Li-raglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 375, 311-322. <br>https://doi.org/10.1056/NEJMoa1603827Müller, T.D., Finan, B., Bloom, S.R., et al. (2019) Glucagon-Like Peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. <br>https://doi.org/10.1016/j.molmet.2019.09.010O’neil, P.M., Birkenfeld, A.L., Mcgowan, B., et al. (2018) Efficacy and Safety of Semaglutide Compared with Liraglutide and Placebo for Weight Loss in Patients with Obesity: A Randomised, Double-Blind, Placebo and Active Controlled, Dose-Ranging, Phase 2 Trial. The Lancet, 392, 637-649. <br>https://doi.org/10.1016/S0140-6736(18)31773-2Kadouh, H., Chedid, V., Halawi, H., et al. (2020) GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. The Journal of Clinical Endocrinology & Metabolism, 105, 1552-1563. <br>https://doi.org/10.1210/clinem/dgz140Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015) A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. The New England Journal of Medicine, 373, 11-22. <br>https://doi.org/10.1056/NEJMoa1411892Hurren, K.M. and Berlie, H.D. (2011) Lorcaserin: An Investigation-al Serotonin 2C Agonist for Weight Loss. American Journal of Health-System Pharmacy, 68, 2029-2037. <br>https://doi.org/10.2146/ajhp100638Shukla, A.P., Kumar, R.B. and Aronne, L.J. (2015) Lorcaserin HCL for the Treatment of Obesity. Expert Opinion on Pharmacotherapy, 16, 2531-2538. <br>https://doi.org/10.1517/14656566.2015.1096345Lorcaserin, M. (2012) LiverTox: Clinical and Research In-formation on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethes-da.Sharretts, J., Galescu, O. and Gomatam, S., et al. (2020) Cancer Risk Associated with Lorcaserin—The FDA’s Review of the CAMELLIA-TIMI 61 Trial. The New England Journal of Medicine, 383, 1000-1002.
<br>https://doi.org/10.1056/NEJMp2003873